March 29, 2019
With the help of Marker's technology, a population of T-cells attacks multiple cancer targets and works to activate a patient's immune system to trigger anti-tumor activity.
March 28, 2019
Company to host business update call and webcast today at 5:00 p.m. EDT
March 18, 2019
Marker Therapeutics announces business update conference call and webcast on Thursday, March 28th.
March 15, 2019
DLBCL data was particularly impressive. Patients who were third and fourth line refractory and relapsed post-transplant are experiencing durable and long responses with some now five years in remission.